Close

Anti-Peptide SIF T cell receptor (OT-III), pCDTCR1 (TCR-YC0958)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

OT-3 TCR binds SIFNFEKL (F3) and SIVNFEKL (V3). V3- and F3-primed effector T cells exhibited a normal pattern of CD44 and CD62L expression and secreted IFN-γ and TNF.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide SIF
  • Epitope
  • SIFNFEKL
  • Format
  • Non-Modified TCR
  • Allele
  • H2-Kb
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • OT-III
  • Host Species
  • Mouse

Target

  • Introduction
  • Low avidity autoreactive T cells have been detected in several experimental setups and they can best be studied in transgenic systems expressing a model antigen as a neo self-antigen. Such a setup allowed us to directly compare the quality of antigenspecific T cells that can be found in the presence or the absence of the neo self-antigen. Rat insulin promoter (Rip)–mOva mice express a membrane-bound form of Ova in mTec in the thymus, the β cells in the islets of Langerhans in the pancreas, the proximal tubular epithelial cells in the kidneys, and, in the case of male mice, in the testis.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide SIF T cell receptor (OT-III), pCDTCR1 (TCR-YC0958). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.